Cover Image
市場調查報告書

危急性肢體缺血:開發中產品分析

Critical Limb Ischemia - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 219779
出版日期 內容資訊 英文 145 Pages
訂單完成後即時交付
價格
Back to Top
危急性肢體缺血:開發中產品分析 Critical Limb Ischemia - Pipeline Review, H2 2016
出版日期: 2016年11月16日 內容資訊: 英文 145 Pages
簡介

所謂危急性肢體缺血是週邊動脈疾病(PAD)中最危及生命的症狀。一般是由於動脈粥狀硬化性心血管疾病相關的慢性發炎過程所造成。主要的症狀有腳·腳尖的疼痛和發麻、潰爛、皮膚感染疾病等,無論是何者在發症後都無法治療。這個疾病的治療目的在於減輕危及冠狀動脈的風險要素(禁煙、減輕膽固醇等)、減輕疼痛、治癒潰瘍、避免截肢手術、改善生活品質、提升生存率等。

本報告提供全球各國治療危急性肢體缺血(CLI)所用的開發中產品之開發情形相關分析,提供您產品開發·上市的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

簡介

  • 調查範圍

危急性肢體缺血概要

治療藥的開發

  • 開發中產品的概要
  • 開發中產品比較分析

危急性肢體缺血:企業開發中的治療藥

危急性肢體缺血:大學/機關研究中的治療藥

危急性肢體缺血:開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品

危急性肢體缺血:企業開發中的產品

危急性肢體缺血:大學/機關研究中的產品

危急性肢體缺血治療藥的開發企業

  • AnGes MG, Inc.
  • Apceth GmbH & Co. KG
  • Athersys, Inc.
  • Caladrius Biosciences, Inc.
  • Cynata Therapeutics Limited
  • Hemostemix Ltd
  • Histocell S.L.
  • ID Pharma Co., Ltd.
  • IntelliCell BioSciences Inc.
  • Juventas Therapeutics, Inc.
  • Kasiak Research Private Limited
  • 興和
  • Multi Gene Vascular Systems Ltd
  • Pharmicell Co., Ltd.
  • Pluristem Therapeutics Inc.
  • ReNeuron Group Plc
  • Stempeutics Research Private Limited
  • Targazyme, Inc.
  • TikoMed AB
  • U.S. Stem Cell, Inc.
  • Vericel Corporation
  • ViroMed Co., Ltd.

危急性肢體缺血:治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

危急性肢體缺血:最近的開發平台趨勢

危急性肢體缺血:暫停中的計劃

危急性肢體缺血:開發中止的產品

危急性肢體缺血:產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8647IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Critical Limb Ischemia - Pipeline Review, H2 2016, provides an overview of the Critical Limb Ischemia (Cardiovascular) pipeline landscape.

Critical limb ischemia (CLI) is the most severe form of peripheral arterial disease (PAD). It is caused by chronic inflammatory processes associated with atherosclerosis that result in reduced blood flow to the legs, feet and hands. Symptoms include pain or numbness in feet or toes, sores, skin infections will not heal. Treatment goals for CLI include reducing the number of cardiovascular risk factors (such as quitting smoking and reduction of cholesterol), relieving pain, healing ulcers, preventing major amputation, improving quality of life and increasing survival.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Critical Limb Ischemia - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Critical Limb Ischemia (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Critical Limb Ischemia (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Critical Limb Ischemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 11, 4, 12 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.Critical Limb Ischemia.

Critical Limb Ischemia (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Critical Limb Ischemia (Cardiovascular).
  • The pipeline guide reviews pipeline therapeutics for Critical Limb Ischemia (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Critical Limb Ischemia (Cardiovascular) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Critical Limb Ischemia (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Critical Limb Ischemia (Cardiovascular)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Critical Limb Ischemia (Cardiovascular).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Critical Limb Ischemia (Cardiovascular) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Critical Limb Ischemia Overview
  • Therapeutics Development
    • Pipeline Products for Critical Limb Ischemia - Overview
    • Pipeline Products for Critical Limb Ischemia - Comparative Analysis
  • Critical Limb Ischemia - Therapeutics under Development by Companies
  • Critical Limb Ischemia - Therapeutics under Investigation by Universities/Institutes
  • Critical Limb Ischemia - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Critical Limb Ischemia - Products under Development by Companies
  • Critical Limb Ischemia - Products under Investigation by Universities/Institutes
  • Critical Limb Ischemia - Companies Involved in Therapeutics Development
    • AnGes MG, Inc.
    • Apceth GmbH & Co. KG
    • Athersys, Inc.
    • BiogenCell Ltd.
    • Caladrius Biosciences Inc
    • Cynata Therapeutics Limited
    • Hemostemix Ltd
    • Histocell S.L.
    • ID Pharma Co., Ltd.
    • Integene International Holdings LLC
    • Juventas Therapeutics, Inc.
    • Kasiak Research Private Limited
    • Kowa Company, Ltd.
    • Neurofx, Inc.
    • Pharmicell Co., Ltd.
    • Pluristem Therapeutics Inc.
    • ReNeuron Group Plc
    • Symic Biomedical, Inc.
    • Targazyme, Inc.
    • TikoMed AB
    • U.S. Stem Cell, Inc.
    • Vericel Corporation
    • VESSL Therapeutics Ltd
    • ViroMed Co Ltd
  • Critical Limb Ischemia - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • ACP-01 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AdipoCell - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Alecmestencel-T - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ASCT-01 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BC-1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • beperminogene perplasmid - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Biologic to Activate FGF2 for Critical Limb Ischemia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Cellgram-CLI - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CLBS-12 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DVC-10101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • FAB-117HC - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Gene Therapy for Critical Limb Ischemia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ixmyelocel-T - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • JVS-100 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MultiGeneAngio - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NFx-101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NK-104 NP - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PF-05285401 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PLX-PAD - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Protein to Agonize LRP5 and LRP6 for Critical Limb Ischemia and Myocardial Infarction - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Refacell-CLI - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Rejuveinix - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ReN-009 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SB-030 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Stem Cell Therapy for Cardiovacular Diseases and Asthma - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Stem Cell Therapy for Critical Limb Ischemia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Stem Cell Therapy for Critical Limb Ischemia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TM-700 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TXA-302 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TZ-101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VM-202 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Critical Limb Ischemia - Dormant Projects
  • Critical Limb Ischemia - Discontinued Products
  • Critical Limb Ischemia - Product Development Milestones
    • Featured News & Press Releases
      • Oct 03, 2016: Hemostemix Announces it has been Granted two Additional Patents in the US and in Canada
      • Jun 20, 2016: AnGes Announces Amendment to the Global Development of HGF Plasmid for Critical Limb Ischemia
      • Apr 18, 2016: Hemostemix Receives IRB Approval from the Houston Methodist Hospital Research Institute and the University of California Los Angeles
      • Apr 18, 2016: Caladrius Reaches Agreement with Japanese Regulators on Development Plan for CD34 Cell Therapy for Critical Limb Ischemia
      • Jan 22, 2016: ViroMed Publishes Results from Critical Limb Ischemia Phase II Clinical Study
      • Dec 22, 2015: Hemostemix Poised to Expand Phase-2 Clinical Trial of Lead Product ACP-01 to the United States
      • Oct 05, 2015: Hemostemix to Present at 2015 Stem Cell Meeting on the Mesa
      • Sep 14, 2015: Hemostemix Executes Strategic Alliance with Hemostemix Asia for Expansion of Phase-2 Clinical Trial to Taiwan
      • Aug 12, 2015: Patient Enrollment Begins in Europe in the Global Phase III Clinical Trial of HGF Gene Therapy for Critical Limb Ischemia
      • Aug 10, 2015: Hemostemix Receives FDA Clearance for Phase-2 Clinical Trial of Lead Product ACP-01 in the United States
      • Jul 27, 2015: Hemostemix Enrolls 20th Participant and Treats 15th in International Clinical Trial for Critical Limb Ischemia
      • Jun 25, 2015: Hemostemix Enrolls Fifth Participant at Vancouver General Hospital in International Phase-2 Clinical Trial for Critical Limb Ischemia
      • Jun 18, 2015: Hemostemix Prepares Investigational New Drug Application for Review by U.S. Food and Drug Administration for Company's ACP-01 Formulation to Treat Critical Limb Ischemia
      • May 19, 2015: Hemostemix Receives Notice of Allowance for Additional U.S. Patent on ACP-01 Covering Autologous Cell Therapy for Critical Limb Ischemia
      • Apr 20, 2015: Hemostemix to Present at the 2015 Annual Meeting of the Clinical Trials Association in Israel
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Critical Limb Ischemia, H2 2016
  • Number of Products under Development for Critical Limb Ischemia - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Development by Companies, H2 2016 (Contd..1)
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Investigation by Universities/Institutes, H2 2016
  • Critical Limb Ischemia - Pipeline by AnGes MG, Inc., H2 2016
  • Critical Limb Ischemia - Pipeline by Apceth GmbH & Co. KG, H2 2016
  • Critical Limb Ischemia - Pipeline by Athersys, Inc., H2 2016
  • Critical Limb Ischemia - Pipeline by BiogenCell Ltd., H2 2016
  • Critical Limb Ischemia - Pipeline by Caladrius Biosciences Inc, H2 2016
  • Critical Limb Ischemia - Pipeline by Cynata Therapeutics Limited, H2 2016
  • Critical Limb Ischemia - Pipeline by Hemostemix Ltd, H2 2016
  • Critical Limb Ischemia - Pipeline by Histocell S.L., H2 2016
  • Critical Limb Ischemia - Pipeline by ID Pharma Co., Ltd., H2 2016
  • Critical Limb Ischemia - Pipeline by Integene International Holdings LLC, H2 2016
  • Critical Limb Ischemia - Pipeline by Juventas Therapeutics, Inc., H2 2016
  • Critical Limb Ischemia - Pipeline by Kasiak Research Private Limited, H2 2016
  • Critical Limb Ischemia - Pipeline by Kowa Company, Ltd., H2 2016
  • Critical Limb Ischemia - Pipeline by Neurofx, Inc., H2 2016
  • Critical Limb Ischemia - Pipeline by Pharmicell Co., Ltd., H2 2016
  • Critical Limb Ischemia - Pipeline by Pluristem Therapeutics Inc., H2 2016
  • Critical Limb Ischemia - Pipeline by ReNeuron Group Plc, H2 2016
  • Critical Limb Ischemia - Pipeline by Symic Biomedical, Inc., H2 2016
  • Critical Limb Ischemia - Pipeline by Targazyme, Inc., H2 2016
  • Critical Limb Ischemia - Pipeline by TikoMed AB, H2 2016
  • Critical Limb Ischemia - Pipeline by U.S. Stem Cell, Inc., H2 2016
  • Critical Limb Ischemia - Pipeline by Vericel Corporation, H2 2016
  • Critical Limb Ischemia - Pipeline by VESSL Therapeutics Ltd, H2 2016
  • Critical Limb Ischemia - Pipeline by ViroMed Co Ltd, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Critical Limb Ischemia - Dormant Projects, H2 2016
  • Critical Limb Ischemia - Dormant Projects (Contd..1), H2 2016
  • Critical Limb Ischemia - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Critical Limb Ischemia, H2 2016
  • Number of Products under Development for Critical Limb Ischemia - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Targets, H2 2016
  • Number of Products by Stage and Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Top 10 Routes of Administration, H2 2016
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top